Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0000737
Disease: Abdominal Pain
Abdominal Pain
0.100 Biomarker phenotype HPO
Abnormal form of the vertebral bodies
0.100 Biomarker phenotype HPO
CUI: C0349705
Disease: Abnormal hemoglobin finding
Abnormal hemoglobin finding
0.100 Biomarker phenotype HPO
CUI: C4023026
Disease: Abnormal megakaryocyte morphology
Abnormal megakaryocyte morphology
0.100 Biomarker disease HPO
CUI: C0855742
Disease: Abnormal platelet morphology
Abnormal platelet morphology
0.100 Biomarker phenotype HPO
CUI: C0023440
Disease: Acute Erythroblastic Leukemia
Acute Erythroblastic Leukemia
0.010 AlteredExpression disease BEFREE All FAB M6 and M7 and trilineal leukaemias expressed mRNAs for alpha-globin, glycoprotein IIb (GpIIb), erythropoietin receptor (Epo-R) and thrombopoietin receptor (c-mpl), but not for myeloperoxidase (MPO) which in contrast was expressed in the other FAB-subtype leukaemias. 9753066 1998
CUI: C0085669
Disease: Acute leukemia
Acute leukemia
0.110 GeneticVariation disease BEFREE These mutations include JAK2, CALR and MPL mutations as the main disease drivers, mutations driving clonal expansion, and mutations that contribute to progression of chronic MPNs to myelodysplasia and acute leukemia. 31741139 2020
CUI: C0085669
Disease: Acute leukemia
Acute leukemia
0.110 Biomarker disease HPO
CUI: C0023449
Disease: Acute lymphocytic leukemia
Acute lymphocytic leukemia
0.010 GeneticVariation disease BEFREE Retrospective molecular studies detected a MPL W515S homozygous mutation in both the initial and remission marrows for B-ALL, at 30-40% and 80% dosage effect, respectively. 25453399 2015
CUI: C0023462
Disease: Acute Megakaryocytic Leukemias
Acute Megakaryocytic Leukemias
0.010 Biomarker disease BEFREE Our results establish that concomitant activation of RBPJ (Notch signaling) and MPL (cytokine signaling) transforms cells of the megakaryocytic lineage and suggest that specific targeting of these pathways could be of therapeutic value for human AMKL. 19287095 2009
Acute panmyelosis with myelofibrosis
0.010 Biomarker disease BEFREE In total, 199 patients with MPN (54 primary myelofibrosis [PMF], 79 essential thrombocythemia [ET], 58 polycythemia vera [PV], and eight MPN-unclassifiable [MPN-U]) and 4 patients with acute panmyelosis with myelofibrosis (APMF) were retrospectively subjected to Sanger sequencing for CALR, JAK2, and MPL. 25873496 2015
CUI: C0023487
Disease: Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia
0.010 Biomarker disease BEFREE In conclusion, CD110 and CD33 reactivity may be useful to distinguish APL from NPM-mutated AML with CD15, CD34 and HLA-DR negativity. 21812014 2012
CUI: C0278878
Disease: Adult Glioblastoma
Adult Glioblastoma
0.020 Biomarker disease BEFREE The thrombopoietin receptor agonist romiplostim improves exposure to chemotherapy in patients with glioblastoma experiencing temozolomide-induced thrombocytopenia. 31586022 2019
CUI: C0278878
Disease: Adult Glioblastoma
Adult Glioblastoma
0.020 Biomarker disease BEFREE The magnetic PLGA/MPLs nanosphere may be another option for treatment of glioblastoma. 22961067 2012
CUI: C0220630
Disease: Adult Liver Carcinoma
Adult Liver Carcinoma
0.010 Biomarker disease BEFREE In particular, besides some cytokines like IFN-α and IL-2, several Toll-like receptor (TLR) agonists like BCG, MPL, and imiquimod are also licensed to be used in patients with several malignancies nowadays, and the first artificial small noncoding RNA (microRNA) mimic, MXR34, has entered phase I clinical study against liver cancer, implying their potential application in cancer therapy. 27240457 2016
CUI: C1332206
Disease: Adult Lymphoma
Adult Lymphoma
0.010 AlteredExpression disease BEFREE Expression of thrombopoietin and thrombopoietin receptor MPL in human leukemia-lymphoma and solid tumor cell lines. 8960108 1996
CUI: C0278876
Disease: Adult Medulloblastoma
Adult Medulloblastoma
0.300 Biomarker disease CTD_human Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. 19270706 2009
CUI: C3900098
Disease: Adult Myelodysplastic Syndrome
Adult Myelodysplastic Syndrome
0.020 GeneticVariation disease BEFREE The gene for the thrombopoietin receptor, c-mpl, has been shown to be overexpressed at the mRNA level in acute myeloid leukemia (AML) and myelodysplastic syndrome. 9933137 1999
CUI: C3900098
Disease: Adult Myelodysplastic Syndrome
Adult Myelodysplastic Syndrome
0.020 GeneticVariation disease BEFREE We report a patient with a JAK2 V617F-negative myeloproliferative/myelodysplastic syndrome who had abnormal megakaryocytic pSTAT5 expression and a MPL W515L mutation. 18479730 2008
CUI: C0149793
Disease: Amaurosis Fugax
Amaurosis Fugax
0.100 Biomarker phenotype HPO
CUI: C0398639
Disease: Amegakaryocytic thrombocytopenia
Amegakaryocytic thrombocytopenia
0.110 Biomarker disease HPO
CUI: C0398639
Disease: Amegakaryocytic thrombocytopenia
Amegakaryocytic thrombocytopenia
0.110 GeneticVariation disease BEFREE To our knowledge, this is the first report that describes a case of amegakaryocytic thrombocytopenia that is not caused by a mutation in MPL and demonstrates the severe impairment of GPVI expression on platelets. 18194481 2008
CUI: C0002871
Disease: Anemia
Anemia
0.130 Biomarker disease HPO
CUI: C0002871
Disease: Anemia
Anemia
0.130 GeneticVariation disease BEFREE Congenital amegakaryocytic thrombocytopenia (CAMT) is caused by the loss of thrombopoietin receptor-mediated (MPL-mediated) signaling, which causes severe pancytopenia leading to bone marrow failure with onset of thrombocytopenia and anemia prior to leukopenia. 23908116 2013
CUI: C0002871
Disease: Anemia
Anemia
0.130 GeneticVariation disease BEFREE Median mutation levels in pretreatment ET samples were significantly higher for MPL-mutated cases (60%) than for JAK2-mutated cases (24%; P=0.01), as was presentation with anemia. 20113830 2010